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Background: Evidence points to the emergence of a novel human coronavirus, Middle East respiratory syndrome
coronavirus (MERS-CoV), which causes a severe acute respiratory syndrome (SARS)-like disease. In response, the
development of effective vaccines and therapeutics remains a clinical priority. To accomplish this, it is necessary to
evaluate neutralizing antibodies and screen for MERS-CoV entry inhibitors.
Methods: In this study, we produced a pseudovirus bearing the full-length spike (S) protein of MERS-CoV in the
Env-defective, luciferase-expressing HIV-1 backbone. We then established a pseudovirus-based inhibition assay to
detect neutralizing antibodies and anti-MERS-CoV entry inhibitors.
Results: Our results demonstrated that the generated MERS-CoV pseudovirus allows for single-cycle infection of a
variety of cells expressing dipeptidyl peptidase-4 (DPP4), the confirmed receptor for MERS-CoV. Consistent with the
results from a live MERS-CoV-based inhibition assay, the antisera of mice vaccinated with a recombinant protein
containing receptor-binding domain (RBD, residues 377–662) of MERS-CoV S fused with Fc of human IgG exhibited
neutralizing antibody response against infection of MERS-CoV pseudovirus. Furthermore, one small molecule HIV
entry inhibitor targeting gp41 (ADS-J1) and the 3-hydroxyphthalic anhydride-modified human serum albumin
(HP-HSA) could significantly inhibit MERS-CoV pseudovirus infection.
Conclusion: Taken together, the established MERS-CoV inhibition assay is a safe and convenient pseudovirus-based
alternative to BSL-3 live-virus restrictions and can be used to rapidly screen MERS-CoV entry inhibitors, as well as
evaluate vaccine-induced neutralizing antibodies against the highly pathogenic MERS-CoV.
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In April, 2012, a severe acute respiratory syndrome
(SARS)-like disease emerged in Saudi Arabia [1-3]. As of
August 13, 2013, the World Health Organization (WHO)
had received reports of 94 cases of infection caused by
this novel human coronavirus, Middle East respiratory
syndrome coronavirus (MERS-CoV, previous name hCoV-
EMC), including 47 deaths, from several countries, includ-
ing Saudi Arabia, Qatar, Jordan, the United Arab Emirates,
the United Kingdom, France, Germany, Italy, and Tunisia
(http://www.who.int/csr/disease/coronavirus_infections/
update_20130813/en/). Eight MERS-CoV clusters have
been reported, suggesting person-to-person transmis-
sion of the disease [4]. However, the transmissibility
of MERS-CoV appears to be less efficient than that of
SARS-coronavirus (SARS-CoV), the first new infectious
disease identified in the 21st century with an approximate
mortality rate of 10% [5].
Genetically, MERS-CoV is closely related to SARS-CoV
[1,6]. Clinically, severe respiratory illness with renal failure
caused by MERS-CoV infection is very similar to the
symptomology related to SARS [2]. Therefore, the out-
break of MERS-CoV infection has raised serious concerns
of a potential global pandemic on the order of SARS in
2003. Accordingly, pursuant to the development of effect-
ive vaccines and antiviral agents, the first step requires
identification of the neutralizing and inhibitory activities of
such anti-MERS-CoV vaccines and therapeutics.
It is now well known that SARS-CoV gains cellular
entry through its receptor, angiotensin converting enzymeTable 1 Cell lines used for detection of MERS-CoV pseudoviru
Cell lines Origin Provider
Huh-7 Human liver Dr. Charles M.
HEP-G2 Human liver ATCC
HT-1080 Human fibrosarcoma ATCC
MT-2 Human lymphocyte NIH AIDS Reag
Hep-2 Human respiratory tract ATCC
Caco-2 Human intestinal tract ATCC
HeLa Human genitourinary tract ATCC
293T Human kidney ATCC
ACE2-293T 293T-derived cells Laboratory sto
A549 Human lung ATCC
NBL-7 Mink lung ATCC
PK15 Pig kidney ATCC
MDCK Canine kidney ATCC
FRhK-4 Fetal rhesus monkey kidney ATCC
Vero African green monkey kidney ATCC
Vero E6 African green monkey kidney ATCC
MA-104 African green monkey kidney ATCC2 (ACE2) [7], whereas MERS-CoV utilizes dipeptidyl
peptidase-4 (DPP4, also known as CD26) as its entry re-
ceptor [8]. Similar to SARS-CoV, the spike (S) protein of
MERS-CoV also plays important roles in receptor binding
and viral entry [5,9]. As the major protein causing virus in-
fection, S protein is an ideal target for both vaccines and
MERS-CoV entry inhibitors.
In this study, we produced a pseudovirus bearing the
full-length S protein of MERS-CoV in the Env-defective,
luciferase-expressing HIV-1 backbone. We then established
a pseudovirus-based inhibition assay for the detection of
neutralizing antibodies and anti-MERS-CoV entry inhibi-
tors. This method was proven to be safe, convenient, reli-
able and effective for the rapid detection of neutralizing
antibodies and viral entry inhibitors against MERS-CoV.
Results
Generated MERS-CoV pseudovirus was able to infect a
variety of cell types from human and non-human hosts
We first detected the ability of the generated MERS-
CoV pseudovirus to infect cells from various tissues and
different hosts, including human cell lines Huh-7, HT-
1080, Hep-2, HEP-G2, A549, MT-2, Caco-2, HeLa and
293T, as well as those from mink (NBL-7), pig (PK15),
canine (MDCK), and monkey (FRhK-4, Vero, Vero E6
and MA-104) (Table 1). Pseudovirus expressing VSV-G
was included as the positive control. The target cells
were respectively infected with MERS-CoV pseudovirus
normalized for equal HIV-1 p24 content, and luciferase
activity was measured at 72 h after infection. As showns infectivity and receptor DPP4 expression
Note
Rice at Rockefeller University
ent Program
ck Express SARS-CoV receptor ACE2
Mv1Lu
Vero C1008
Figure 2 Detection of MERS-CoV S and HIV-1 p24 protein
expression in the packaged MERS-CoV pseudovirus and DPP4
protein expression in target cells by Western blot. (A) Detection of
p24 and MERS-CoV S in pseudotyped MERS-CoV. Anti-p24 (1:50) and
MERS-CoV S-specific polyclonal antibodies (1:200) were used for the test.
(B-C) Detection of DPP4 expression in different cell lines. Goat anti-DPP4
(1 μg/ml) was used for the test, and anti-β-actin monoclonal antibodies
(1:5,000, Sigma) were applied as the internal control.
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of animal cells could be infected by the produced
pseudovirus. Particularly, MERS-CoV pseudovirus infected
HT-1080 and SARS receptor-expressing ACE2-293T cells,
maintaining a high infective ability in identified MERS-
CoV receptor DPP4-expressing Huh-7 cells. In addition,
human cell types, such as Hep-2, HEP-G2, A549 and
MT-2, and animal cell types, including FRhK-4, MDCK,
Vero, Vero E6 and NBL-7, were infected by MERS-CoV
pseudovirus to a significantly higher degree than other cell
types, such as PK15, Caco-2 and HeLa. However, no high
infectivity was observed in MA-104. Our results also dem-
onstrated that VSV-G positive control could highly infect
almost all tested cell types, possibly due to the broad host
range of VSV-G in the capability of infecting multiple tis-
sues in various hosts, while Env- pseudovirus negative con-
trol was unable to infect tested cell lines [10] (Figure 1).
Next, we performed Western blot to identify the incorp-
oration of MERS-CoV S in the packaged MERS-CoV
pseudovirus. As shown in Figure 2A, clear bands corre-
sponding to the HIV-1 p24 and MERS-CoV S protein were
identified in the generated pseudovirus of MERS-CoV by
using antibodies against HIV-1 p24 and MERS-CoV S pro-
tein, respectively, while there was only p24, but no MERS-
CoV S antigen, was detected in the VSV-G pseudovirus
containing p24. These data suggest that specific S protein
of MERS-CoV was effectively incorporated into the pack-
aged HIV-1 particle, generating MERS-CoV pseudovirus.
Western blot was also carried out to detect the expression
of DPP4 in cells susceptible to pseudotyped MERS-CoV.
Among the tested cells, PK-15 exhibited the highest
expression of DPP4, followed by Huh-7. While DPP4
was expressed in FRhK4, HEP-G2, Caco-2, Vero, VeroFigure 1 Detection of MERS-CoV pseudovirus infectivity. Cell
tropism of MERS-CoV pseudovirus in a variety of target cells from
human and non-human hosts. VSV-G and Env- pseudoviruses were
used as positive and negative controls, respectively. The data are
expressed as mean relative luciferase units (RLU) ± standard deviation
(SD) of 4 parallel wells in 96-well culture plates. The experiment was
repeated three times, and similar results were obtained.E6, and MDCK cells, a relatively low level of this protein
was detected in the cells of A549 and ACE2/293T cells.
Nevertheless, no DPP4 expression was shown in HT-
1080, Hep-2, MT-2, HeLa, NBL-7, 293T and MA-104
(Figure 2B-C).
MERS-CoV pseudovirus inhibition assay reliably detected
the neutralizing activity of vaccinated animal sera, and the
result was consistent with that of live MERS-CoV-based
inhibition assay
We used MERS-CoV pseudovirus to establish a pseu-
dovirus inhibition assay and evaluated the neutralizing
activity in the sera of mice vaccinated with a recombinant
protein, S-RBD-Fc, containing receptor-binding domain
(RBD, residues 377–662) of MERS-CoV spike (S) fused
with Fc of human IgG [11]. As shown in Figure 3A, three
tested representative mouse sera demonstrated neutraliz-
ing activity (>96%) against MERS-CoV pseudovirus infec-
tion in the DPP4-expressing Huh-7 cells at titers of
1:160, while the control sera from mice immunized with
PBS showed no neutralizing activity against tested pseu-
dovirus. The above sera were further evaluated for neu-
tralizing activity against MERS-CoV infection using a live
MERS-CoV-based inhibition assay. The results indicated
that neutralizing antibodies of these sera (test sera 1–3
and control sera 1–3) corresponded to those tested by
pseudovirus inhibition assay (Figure 3B), suggesting that
Figure 3 Detection of neutralizing antibodies of vaccinated sera
against MERS-CoV infection. Mice were vaccinated with a
recombinant protein expressing RBD of MERS-CoV S protein, and
representative sera (Sera 1–3) collected from 10 days post-2nd vaccine
were used for the test. Control sera were collected from mice injected
with PBS. (A) MERS-CoV pseudovirus-based inhibition assay in DPP4-
expreesing Huh-7 cells. The data are presented as mean percentages of
inhibition ± SD of duplicate wells. (B) MERS-CoV live virus-based
inhibition assay in Vero E6 cells. The titers were determined as the
highest serum dilutions that completely prevent CPE in at least 50% of
the wells (NT50) and are expressed as mean ± SD. The experiment was
repeated three times, and similar results were obtained. Figure 4 Detection of inhibitory ability of synthetic compounds
against MERS-CoV pseudovirus infection. Compounds (HP-HSA
and ADS-J1) and peptides (C34 and T20) were tested for the inhibition
of MERS-CoV pseudovirus entry into target NBL-7 (A) and Huh-7 cells
(B) at concentrations of 20 and 2.5 μM, respectively. VSV-G
pseudotype was included as the negative control. (3) Detection of the
potential cytotoxicity of the compounds to Huh-7 cells. The data are
presented as mean percentages of inhibition (or cytotoxicity) ± SD of
duplicate wells. The experiment was repeated three times, and similar
results were obtained.
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ficiently reliable to evaluate neutralizing antibodies in-
duced by candidate vaccines against MERS-CoV.
MERS-CoV pseudovirus inhibition assay could be used to
effectively screen for MERS-CoV entry inhibitors
Using the established method, we next detected the in-
hibition activity of several HIV entry inhibitors for their
inhibitory activity on MERS-CoV entry in the NBL-7 and
Huh-7 cells. As shown in Figure 4A, a small molecule HIV
entry inhibitor targeting gp41 (ADS-J1) [12,13] and the 3-
hydroxyphthalic anhydride-modified human serum albu-
min (HP-HSA) targeting HIV-1 gp120 and HIV-1 receptor,
CD4 [14] could inhibit >90% and >68% of MERS-CoVpseudovirus infection at the concentration of 20 and
2.5 μM, respectively, when tested in NBL-7 cells. However,
the highly potent peptidic HIV entry inhibitors, C34 and
T20 [15], showed moderate inhibitory activity on MERS-
CoV pseudovirus infection at 2.5 and 20 μM. To further
confirm our results, we detected the inhibitory ability of
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peptides in the DPP4-expressing cell line Huh-7 [8]. Inter-
estingly, the results were similar to those for the same
compounds tested in NBL-7 cells, with around 90% of
MERS-CoV pseudovirus entry inhibition at concentrations
of 20 μM (Figure 4B). These two compounds, which carry
net negative charges, may interact with the positively
charge residues in the spike protein of the pseudotyped
MERS-CoV, in a similar way as they inhibited infection of
HIV [12-14]and other enveloped viruses, such as inhibition
of SARS-CoV infection by ADS-J1 [16] and inhibition of
human papilloma virus (HPV) infection by HP-HSA [17].
However, C34 and T20 peptides at 20 μM did not show
any inhibitory activity in Huh-7 (Figure 4B), suggesting
that these peptides are unable to inhibit MERS-COV
pseudovirus entry into the DPP4-expressing Huh-7 cells.
As expected, none of the compounds inhibited pseu-
dotypes containing VSV-G when tested in NBL-7 and
Huh-7 cell lines (Figure 4A and 4B).
We then detected the potential cytotoxicity of the
identified compounds to Huh-7 cells that were used for
testing their inhibitory activity on MERS-CoV pseu-
dovirus. As shown in Figure 4C, HP-HSA had no signifi-
cant cytotoxicity at the concentration as high as 100 μM.
ADS-J1 exhibited some cytotoxicity to Huh-7 cells with
CC50 (the concentration causing 50% cytotoxicity) of
26.9 μM. However, its IC50 (the concentration causing
50% inhibition of MERS-CoV pseudovirus infection) is
0.6 μM and its selective index (CC50/IC50) is about 45.
These data indicated that the decreased infectivity of the
peudotyped MERS-CoV in the presence of these com-
pounds is not due to their cytotoxicity, but is associated
with their inhibition on MERS-CoV entry. These results
confirmed that the established pseudovirus inhibition
assay could be used as an effective way to rapidly screen
MERS-CoV entry inhibitors.
Discussion
Angiotensin-converting enzyme 2 (ACE2) has been con-
firmed as the receptor of SARS-CoV [7], while MERS-
CoV has been shown to bind target cells using DPP4 as
its receptor [8]. In this study, we generated a pseu-
dotyped MERS-CoV based on the viral surface S protein,
and detected its infectivity in different cell types. Indeed,
the generated pseudovirus was able to infect a variety of
cell lines, including human and non-human cell types.
Generally, its cell susceptibility was consistent with that
of wildtype MERS-CoV reported previously [18], being
able to maintain high infectivity in DPP4-expressing
cells, such as Huh-7, MDCK, Vero, Vero E6, FRhK4,
HEP-G2, and A549, and incapable of infecting HeLa and
MA-104 cells with no DPP4 expression. Its infectivity to
DPP4-expressing PK-15 and Caco-2 cells was relatively
lower than that of wildtype virus [18]. This is possiblybecause that pseudotyped MERS-CoV, which contains only
viral S protein with ability of single-cycle infection but
lacks the capability for multiple rounds of replication,
might have lower infectivity than wildtype MERS-CoV that
contains all viral proteins necessary for virus replication.
It is noted that MERS-CoV pseudovirus had a rela-
tively higher infectivity in HT-1080, Hep-2, MT-2 and
NBL-7 cells with undetectable DPP4 expression, sug-
gesting that the infectivity of MERS-CoV pseudovirus
might not be completely associated with the expression
level of DPP4. Similar phenomena were observed by
Pohlmann and the colleagues, showing that the lentiviral
pseudotype had a lower infectivity in DPP4-expressing
A549 and that 293T cells from different batches main-
tained variant infectivities [9]. Reports have shown that
HEK cells with undetectable DPP4 had relatively higher
infectivity to wildtype MERS-CoV [18]. It may be pos-
sible that like SARS-CoV, which has alternative receptors
(such as DC-SIGN and/or L-SIGN) in addition to ACE2
[5,19,20], MERS-CoV might also have an alternative re-
ceptor that has not been identified so far.
Notably, the peptides derived from the HIV-1 gp41
HR2 region, C34 and T20, had a moderate inhibitory activ-
ity on MERS-CoV entry into NBL-7 cells, but exhibited no
inhibition on MERS-CoV entry into Huh-7 cells. These re-
sults suggest that C34 and T20 peptides may interact with
the HR1 conformation of MERS-CoV S protein S2 subunit
induced by the binding of S1 subunit to the not-yet-identi-
fied alternative receptor on NBL-7 cells. However, these
peptides may not be able to interact with the HR1 con-
formation of MERS-CoV S protein S2 subunit induced by
the binding of S1 subunit to the well-defined receptor
DPP4 on Huh-7 cells.
Live virus-based inhibition assays have generally been
used to detect neutralizing antibodies against infection
of SARS-CoV or other coronaviruses [21,22]. However,
to carry out this type of inhibition assay, it is necessary
to utilize biosafety level 3 (BSL-3) facilities. Unfortu-
nately, this strict condition is often inconvenient and
cannot be accessed by many researchers. In contrast, our
pseudovirus-based inhibition assay can be performed
without the requirement of BSL-3 laboratories, consider-
ably simplifying the detection of neutralizing antibodies,
as this method does not involve live viruses and is, there-
fore, safe to carry out [10,23]. Moreover, we demon-
strated consistency of neutralization results between the
live virus-based inhibition assay and the established
pseudovirus-based inhibition assay. These neutralizing re-
sults are also consistent with those obtained from the ex-
periments on antisera of mice immunized by another RBD
fragment containing residues 358–588 of MERS-CoV S
protein, as reported recently [24]. The above results sug-
gest a viable alternative for the rapid detection of neutraliz-
ing antibodies against MERS-CoV natural infection and
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3 facilities are not available. Furthermore, in the absence of
BSL-3 facilities, the pseudovirus-based inhibition assay
provides a convenient and reliable way to rapidly screen
compound- or peptide-based MERS-CoV entry inhibi-
tors to test neutralizing antibodies. With easy production
of pseudovirus, rapid read-out and detection of inhib-
ition, this method is particularly suitable for handling a
large variety of samples in a short period of time.
Conclusion
Our study showed that the established MERS-CoV inhib-
ition assay is a safe and convenient pseudovirus-based al-
ternative to BSL-3 live-virus restrictions and can be used
to rapidly screen MERS-CoV entry inhibitors, as well as
evaluate vaccine-induced neutralizing antibodies against
the highly pathogenic MERS-CoV.
Methods
Ethics statement
The study of animals was approved by the Institutional
Animal Care and Use Committee at the New York Blood
Center (Approval #194.14). All animal studies were carried
out in strict accordance with the recommendations of the
American Veterinary Medical Association (AVMA) Guide-
lines and the approved protocols.
Cell lines
Huh-7, HEP-G2, HT-1080, MT-2, Hep-2, Caco-2, HeLa,
293T, ACE2/293T, A549, NBL-7, PK15, MDCK, FRhK-4,
Vero, Vero E6, and MA-104 cells were used for detec-
tion of pseudovirus infectivity and for identification of
expression of MERS-CoV’s receptor DPP4. Information
on these cell lines as well as their origins and providers
was specifically described in Table 1.
Recombinant plasmid construction
The codon-optimized genes expressing full-length S pro-
tein of MERS-CoV (humanbetacoronavirus 2c EMC/
2012, hCoV-EMC, GenBank accession no. AFS88936.1)
were synthesized by GenScript (Nanjing, China) by re-
placement of the N-terminal signal peptide (residues 1–17)
with CD5 signal sequence and insertion into pcDNA3.1
vector (Invitrogen, Carlsbad, CA). The constructed recom-
binant MERS-CoV plasmid (rMERS-CoV-S) containing
the S gene was confirmed for correct insertion by sequen-
cing analysis.
Production of MERS-CoV pseudovirus bearing S protein
Generation of MERS-CoV pseudovirus was done as pre-
viously described with some modifications [10]. Briefly,
293T cells (ATCC, Manassas, VA) were co-transfected
with 20 μg of plasmid encoding Env-defective, luciferase-
expressing HIV-1 (pNL4-3.luc.RE) and 20 μg of rMERS-CoV-S plasmid, respectively, into a-T175 tissue culture
flask using the calcium phosphate method. Cells were
changed into fresh DMEM 8 h later. Supernatants were
harvested 72 h post-transfection and used for single-
cycle infection. The plasmids encoding vesicular stoma-
titis virus G protein (VSV-G-pcDNA3.1) and pcDNA3.1
vector were co-transfected with pNL4-3.luc.RE plasmid
to generate VSV-G pseudovirus and pseudovirus without
Env (Env-) as controls.
HIV-1 p24
The p24 content in the produced MERS-CoV pseudo-
virus was quantified by ELISA, as previously described,
with some modifications [10]. Briefly, ELISA plates were
precoated with HIVIG (5 μg/ml) overnight at 4°C and
blocked at 37°C for 2 h. Lysed pseudovirus was added to
the plates and incubated at 37°C for 1 h. After washes,
the plates were respectively incubated with anti-p24
mAb (183-H12-5C, 1:20) and then with horseradish per-
oxidase (HRP)-conjugated goat anti-mouse IgG at 37°C
for 1 h. The substrate 3,30,5,50-tetramethylbenzidine
(TMB) (Zymed, Carlsbad, CA) was added, and the reaction
was stopped by 1 N H2SO4. The absorbance at 450 nm
(A450) was measured by ELISA Plate Reader (Tecan, San
Jose, CA).
Detection of MERS-CoV pseudovirus infectivity
To detect infectivity, different target cells (104/well in
96-well plates) from various sources (Table 1) were re-
spectively infected with MERS-CoV pseudovirus. Fresh
DMEM was added 12 h post-infection, and RLU was
measured 72 h later by Ultra 384 luminometer (Tecan).
Western blot
Western blot was performed to detect HIV-1 p24
and MERS-CoV S protein in the generated pseudo-
virus, and to identify expression of DPP4 in cells suscep-
tible to MERS-CoV pseudovirus as previously described
with some modifications [10]. Briefly, lysed pseudovirus
(200 ng/ml p24) or cell lysates (30 μg total proteins) were
respectively separated by 10% Tris-glycine gels, which
were then transferred to nitrocellulose membranes. After
blocking with 5% non-fat milk in PBST overnight at 4°C,
the blots were respectively incubated with anti-p24 (183-
H12-5C, 1:50), anti-S of MERS-CoV (1:200) (prepared
in our laboratory), and goat anti-DPP4 (1 μg/ml, R&D
Systems, Minneapolis, MN), for 1 h at room temper-
ature. After three washes, the blots were then incu-
bated with HRP-conjugated anti-mouse IgG (for HIV-1
p24 and MERS-CoV S, 1:3,000, Invitrogen) or anti-goat
IgG (for DPP4, 1 1:3,000, R&D Systems) for 1 h at room
temperature. Signals were visualized with ECL Western
blot substrate reagents and Amersham Hyperfilm (GE
Healthcare).
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The construction, expression and purification of the re-
combinant protein fused with Fc (S-RBD-Fc) were done
as previously described [11,25]. Briefly, genes encoding
RBD (residues 377–662) of MERS-CoV S protein were
amplified by PCR using synthesized codon-optimized
full-length S sequences of MERS-CoV as the template,
which were then digested by EcoR I and Bgl II restric-
tion enzymes and inserted into the pFUSE-hIgG1-Fc2
expression vector (hereinafter named Fc, InvivoGen, San
Diego, CA). The sequence-confirmed recombinant plasmid
was transfected into 293T cells (ATCC, Manassas, VA)
seeded 24 h before transfection, followed by replacement
of culture medium by serum-free DMEM (Invitrogen,
Carlsbad, CA) 10 h later and then collection of super-
natant containing expressed protein 72 h post-transfection.
The recombinant protein was purified by Protein A affinity
chromatography (GE Healthcare, Piscataway, NJ), accord-
ing to the manufacturer’s instructions.
Mouse vaccination and serum collection
Mice were subcutaneously immunized with 10 μg/mouse
of recombinant MERS-CoV S-RBD-Fc protein formu-
lated with Freund’s complete adjuvant (Sigma, St. Louis,
MO) and boosted once with 5 μg/mouse of the immu-
nogen and Freund’s incomplete adjuvant at 2-week inter-
vals. Sera collected at 10 days post-2nd vaccination were
used to detect neutralizing activity.
MERS-CoV pseudovirus inhibition assay
Pseudovirus inhibition assay was established to detect neu-
tralizing activity of vaccinated mouse sera and inhibitory
ability of antiviral agents against infection of MERS-CoV
pseudovirus in target cells [10]. Briefly, pseudovirus-
containing supernatants were respectively incubated with
serially diluted mouse sera or synthetic compounds at 37°C
for 1 h before adding to target cells preplated in 96-well
culture plates (104 cells/well). Twenty-four hours later, cells
were refed with fresh medium, which was followed by
lysing cells 72 h later using cell lysis buffer (Promega)
and transferring the lysates into 96-well luminometer
plates. Luciferase substrate (Promega) was added to the
plates, and relative luciferase activity was determined.
The inhibition of MERS-CoV pseudovirus was presented
as % inhibition.
MERS-CoV inhibition assay
Neutralizing antibody titers of mouse sera against infec-
tion by MERS-CoV live virus were further detected as
previously described for SARS-CoV with some modifica-
tions [26,27]. Briefly, serial dilutions of mouse sera were
incubated with 100 50% tissue culture infective doses
(TCID50) of virus for 1 h at 37°C prior to addition to the
monolayer of Vero E6 cells in triplicate. Virus supernatantwas removed and replaced with fresh medium after 1 h of
culture at 37°C. Cytopathic effect (CPE) in each well was
observed daily and recorded on day 3 post-infection. The
neutralizing titers of mouse antisera that completely
prevented CPE in 50% of the wells (NT50) were calculated
as before [26-28].
Cytotoxicity assay
The in vitro cytotoxicity of the synthetic compounds to
Huh-7 target cells was measured by the XTT assay as
previously described with some modifications [29]. Briefly,
100 μl of serially diluted compounds in non-color 1640
medium were added to equal volumes of cells (5 × 105/ml)
in 96-well tissue culture plates. After incubation at 37°C
for 3 days, 50 μl of XTT solution (1 mg/ml) containing
0.02 μM of phenazinemethosulphate (PMS) were added.
Four hour later, the absorbance at 450 nm (A450) was
measured with ELISA Plate Reader.
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